Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

2.

Thieblemont

C

,

Phillips

T

,

Ghesquieres

H

, et al.

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

.

J Clin Oncol

.

2023

;

41

(

12

):

2238

-

2247

.

3.

Bannerji

R

,

Arnason

JE

,

Advani

RH

, et al.

Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

.

Lancet Haematol

.

2022

;

9

(

5

):

e327

-

e339

.

4.

Budde

LE

,

Assouline

S

,

Sehn

LH

, et al.

Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study

.

J Clin Oncol

.

2022

;

40

(

5

):

481

-

491

.

5.

Patel

K

,

Riedell

PA

,

Tilly

H

, et al.

A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma: recommended dose safety/efficacy update and escalation exposure-response analysis [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

9470

-

9472

.

6.

Falchi

L

,

Vardhana

SA

,

Salles

GA

.

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

.

Blood

.

2023

;

141

(

5

):

467

-

480

.

7.

Topp

MS

,

Tani

M

,

Dickinson

M

, et al.

Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1775

-

1777

.

8.

Falchi

L

,

Offner

F

,

Belada

D

, et al.

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): phase 1/2 data update

.

J Clin Oncol

.

2022

;

40

(

suppl 16

). 7523.

9.

Lemoine

J

,

Ruella

M

,

Houot

R

.

Born to survive: how cancer cells resist CAR T cell therapy

.

J Hematol Oncol

.

2021

;

14

(

1

):

199

.

10.

Philipp

N

,

Kazerani

M

,

Nicholls

A

, et al.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

.

Blood

.

2022

;

140

(

10

):

1104

-

1118

.

11.

Piccione

EC

,

Belousov

A

,

Hamidi

H

, et al.

Immune correlates of response to glofitamab: biomarker findings from a pivotal phase II expansion study in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

.

HemaSphere

.

2022

;

6

:

1096

-

1097

.

12.

Bachy

E

,

Le Gouill

S

,

Di Blasi

R

, et al.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

.

Nat Med

.

2022

;

28

(

10

):

2145

-

2154

.

13.

Abramson

JS

,

Palomba

ML

,

Gordon

LI

, et al.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

.

Lancet

.

2020

;

396

(

10254

):

839

-

852

.

14.

Neelapu

SS

,

Jacobson

CA

,

Ghobadi

A

, et al.

5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)

.

Blood

.

2023

;

141

(

19

):

2307

-

2315

.

15.

Neelapu

SS

,

Locke

FL

,

Bartlett

NL

, et al.

Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma

.

N Engl J Med

.

2017

;

377

(

26

):

2531

-

2544

.

16.

Schuster

SJ

,

Bishop

MR

,

Tam

CS

, et al.

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2019

;

380

(

1

):

45

-

56

.

17.

Bethge

WA

,

Martus

P

,

Schmitt

M

, et al.

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

.

Blood

.

2022

;

140

(

4

):

349

-

358

.

18.

Jacobson

CA

,

Locke

FL

,

Ma

L

, et al.

Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States

.

Transplant Cell Ther

.

2022

;

28

(

9

):

581.e1

-

581.e8

.

19.

Van Le

H

,

Van Naarden Braun

K

,

Nowakowski

GS

, et al.

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma

.

Leuk Lymphoma

.

2023

;

64

(

3

):

573

-

585

.

20.

Hutchings

M

,

Morschhauser

F

,

Iacoboni

G

, et al.

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

.

J Clin Oncol

.

2021

;

39

(

18

):

1959

-

1970

.

21.

Hutchings

M

,

Mous

R

,

Clausen

MR

, et al.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

.

Lancet

.

2021

;

398

(

10306

):

1157

-

1169

.

22.

Iacoboni

G

,

Iraola-Truchuelo

J

,

Mussetti

A

, et al.

Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

378

-

380

.